Medicare Analysis of EUA Outpatient Ambulatory Therapies Concludes Severe COVID-19 was Avoidable in 16%

Analysis Did not Consider AAPS Home Treatment Guide, Multidrug Protocols Launched in 2020 By Peter A. McCullough, MD, MPH The the medical research community has had blinders on from the very beginning of the pandemic. Review papers and outcomes analysis have ignored the Association of American Physicians and Surgeons Home Treatment Guide published in October, 2020, featuring the McCullough Protocol. Additional protocols from FLCCC, Zelenko, and Raoult used similar principles but did not have the backing of a chartered, established medical society. Yet, the medical orthodoxy has refused to this day to acknowledge any of these protocols existed, were utilized, or resulted in patients not requiring Emergency Use Authorized (EUA) drugs and avoiding hospitalization and death. Wilcock et al, analyzed Medicare fee-for-service claims data and found that from 2021 forward, 23% of patients received acute COVID-19 ambulatory therapy. They concluded that 16% of severe cases could have been avoided. I have testified in the US Senate that two thirds of all American hospitalizations and deaths could have been avoided with full implementation of the McCullough Protocol as soon as it was initially published in The American Journal of Medicine, August 6, 2020, and certainly by October, 2020 with the widely disseminated AAPS Home Treatment Guide. The Wilcock paper is important because the authors point to a preventable fraction. We can only conclude that the proportion of hospitalization and deaths must have been enormous, potentially 85% if we would have had a global “home treatment first” for high-risk patients with their first case of COVID-19. www.aapsonline.org We we should never wait for the government to provide EUA drugs in a pandemic. As Wilcock and colleagues found, these drugs come too late, are poorly utilized, and may not be optimally used in combination with other drugs, so the population benefit is modest. Only early empiric multidrug therapy has the potential for a large, life-saving nationwide impact because its used immediately, leverages signals of benefit and acceptable safety, and is commercially available at the outset of the next pandemic. Share Courageous Discourse™ with Dr. Peter McCullough & John Leake is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Upgrade to paid Please subscribe to Courageous Discourse as a paying or founder member so we can continue to bring you the truth. Peter A. McCullough, MD, MPH President, McCullough Foundation www.mcculloughfnd.org Wilcock AD, Kissler S, Mehrotra A, McGarry BE, Sommers BD, Grabowski DC, Grad YH, Barnett ML. Clinical Risk and Outpatient Therapy Utilization for COVID-19 in the Medicare Population. JAMA Health Forum. 2024 Jan 5;5(1):e235044. doi: 10.1001/jamahealthforum.2023.5044. PMID: 38277170; PMCID: PMC10818223. McCullough PA, Kelly RJ, Ruocco G, Lerma E, Tumlin J, Wheelan KR, Katz N, Lepor NE, Vijay K, Carter H, Singh B, McCullough SP, Bhambi BK, Palazzuoli A, De Ferrari GM, Milligan GP, Safder T, Tecson KM, Wang DD, McKinnon JE, O'Neill WW, Zervos M, Risch HA. Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection. Am J Med. 2021 Jan;134(1):16-22. doi: 10.1016/j.amjmed.2020.07.003. Epub 2020 Aug 7. PMID: 32771461; PMCID: PMC7410805. Courageous Discourse™ with Dr. Peter McCullough & John Leake. © 2024 Peter McCullough MD MPH 548 Market Street PMB 72296, San Francisco, CA 94104